FDA panel supports patisiran for ATTR amyloidosis with cardiomyopathy healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
An FDA advisory committee voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction.
For the first time, a HIF-PHI-class agent won backing from an FDA advisory committee for treating anemia, but the panel voted against daprodustat for adults with chronic kidney disease not on dialysis.